Takeda opens Bengaluru ICC, eyes 750 employees to bolster India presence

Japanese biopharmaceutical giant Takeda has launched its flagship Innovation Capabilities Centre (ICC) in Bengaluru’s Bhartiya City IT Park. The new centre aims to harness India’s technological expertise and expand its workforce to 750 employees by the end of 2025.

Also read: ISRO achieves another milestone with satellite docking technology

The Bengaluru ICC complements Takeda’s existing hubs in Slovakia and Mexico, reflecting the company’s strategic focus on leveraging advanced digital technologies and artificial intelligence (AI) to enhance global healthcare innovation.

The centre will prioritise cutting-edge capabilities such as AI, generative AI (GenAI), and data science to improve healthcare efficiency, predictive analytics, and patient outcomes. It will also focus on device engineering, application virtualisation, and data visualisation to accelerate innovation and foster patient-centric solutions.

Takeda’s diverse therapeutic areas include gastrointestinal disorders, rare diseases, immunology, oncology, and vaccines. The company reported $28.2 billion in revenue for FY23, supported by a $4.8 billion investment in research and development (R&D). With over 180 global R&D partnerships, Takeda is committed to transforming treatments through data-driven innovation.

The Bengaluru ICC underscores Takeda’s long-term vision of harnessing local expertise to address global healthcare challenges and advance its digital transformation strategy.